Due to apparent “deficiencies” in trial data, the FDA has rejected a request to approve Acadia Pharmaceutical’s application for the repurposing of Parkinson’s drug…
Now under review, the drug pimavanserin may become the first FDA-approved treatment for dementia-related psychosis. Roughly 2.4 million Americans experience symptoms of dementia-related psychosis,…
As part of our BrainTalk series, Being Patient spoke with Executive Director of ACADIA Pharmaceuticals Dr. Erin Foff and Chris Schwilk, who lives with…
Phase III trials for experimental dementia-related psychosis treatment pimavanserin draw interest at AAIC; FDA begins consideration of the drug approval. As many as half…